Achaogen Inc (NASDAQ:AKAO) has received an average recommendation of “Hold” from the thirteen ratings firms that are covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $18.22.

A number of equities analysts recently weighed in on AKAO shares. BidaskClub raised Achaogen from a “hold” rating to a “buy” rating in a research note on Monday, June 18th. Mizuho reissued a “buy” rating on shares of Achaogen in a research note on Thursday, May 3rd. Zacks Investment Research cut Achaogen from a “hold” rating to a “sell” rating in a research note on Tuesday, May 1st. lifted their target price on Achaogen to $2.54 and gave the company a “sell” rating in a research note on Tuesday, July 3rd. Finally, ValuEngine raised Achaogen from a “sell” rating to a “hold” rating in a research note on Monday, April 2nd.

In other news, major shareholder Robert W. Duggan purchased 77,247 shares of Achaogen stock in a transaction dated Wednesday, April 25th. The stock was acquired at an average cost of $13.02 per share, for a total transaction of $1,005,755.94. Following the acquisition, the insider now directly owns 7,028,153 shares in the company, valued at $91,506,552.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Robert W. Duggan purchased 119,700 shares of Achaogen stock in a transaction dated Thursday, April 19th. The shares were purchased at an average price of $12.76 per share, with a total value of $1,527,372.00. Following the completion of the acquisition, the insider now owns 6,602,269 shares in the company, valued at $84,244,952.44. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 1,745,013 shares of company stock valued at $21,050,583 and have sold 4,353 shares valued at $46,671. 7.80% of the stock is owned by insiders.

Several institutional investors have recently made changes to their positions in AKAO. Bank of New York Mellon Corp lifted its holdings in Achaogen by 3.6% in the 4th quarter. Bank of New York Mellon Corp now owns 144,843 shares of the biopharmaceutical company’s stock worth $1,555,000 after purchasing an additional 4,999 shares during the last quarter. Swiss National Bank lifted its holdings in Achaogen by 12.9% in the 1st quarter. Swiss National Bank now owns 50,000 shares of the biopharmaceutical company’s stock worth $648,000 after purchasing an additional 5,700 shares during the last quarter. TimesSquare Capital Management LLC lifted its holdings in Achaogen by 0.5% in the 4th quarter. TimesSquare Capital Management LLC now owns 1,367,965 shares of the biopharmaceutical company’s stock worth $14,692,000 after purchasing an additional 6,300 shares during the last quarter. Teachers Advisors LLC lifted its holdings in Achaogen by 15.0% in the 4th quarter. Teachers Advisors LLC now owns 62,483 shares of the biopharmaceutical company’s stock worth $671,000 after purchasing an additional 8,137 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its holdings in Achaogen by 2.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 331,039 shares of the biopharmaceutical company’s stock worth $3,555,000 after purchasing an additional 9,267 shares during the last quarter. Institutional investors and hedge funds own 68.72% of the company’s stock.

Achaogen traded up $0.44, reaching $8.29, during mid-day trading on Friday, Marketbeat.com reports. 1,188,976 shares of the stock were exchanged, compared to its average volume of 1,288,134. The firm has a market cap of $348.52 million, a P/E ratio of -2.62 and a beta of 0.98. Achaogen has a 1-year low of $7.43 and a 1-year high of $25.22. The company has a quick ratio of 7.01, a current ratio of 7.01 and a debt-to-equity ratio of 0.24.

Achaogen (NASDAQ:AKAO) last released its earnings results on Friday, May 4th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.17). The firm had revenue of $2.14 million for the quarter, compared to analyst estimates of $1.25 million. Achaogen had a negative return on equity of 97.86% and a negative net margin of 2,384.08%. sell-side analysts expect that Achaogen will post -3.51 EPS for the current year.

Achaogen Company Profile

Achaogen, Inc, a late-stage biopharmaceutical company, focusses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae.

Analyst Recommendations for Achaogen (NASDAQ:AKAO)

Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.